Team

Carl-Johan Spak

Carl-Johan is a senior advisor at Flerie since April 2021. He has held several positions in pharma companies and has served as director in Flerie companies since 2012. He currently serves as director of several drug development and medtech companies, among them Atrogi, Symcel, EpiEndo, Lipum and Xspray Pharma.

Until 2021, Carl-Johan had a long career within Recipharm, one of the leading CDMOs in the pharma space, where he started in 1995. He holds a PhD in pharmacology and cariology from the Karolinska Institute in Sweden.

Carl-Johan enjoys mountain biking, especially in Lofsdalen, Sweden together with family life with his grandchildren.

Carl-Johan on Linkedin

Cecilia Stureborg von Schéele

Cecilia has been CFO of Flerie Invest since 2021 and deputy CEO since 2023. She has more than 20 years of experience in finance from various positions at Reci­pharm AB (publ), KPMG, and working with the IPO of Viva Wine Group. She has a MSc in International Business Administration from Lund University.

Cecilia enjoys spending time with family and friends over a meal, hiking, and heading to her cottage in southern Närke.

Cecilia on Linkedin

José Ochoa

Karl Elmqvist

Karl is an Investment Manager at Flerie. He is a board member in porfolio companies Strike Pharma and Sixera Pharma, and an observer in AnaCardio. Karl is a medical doctor by training, obtaining his MBBS BSc from Imperial College London where he also spent a year at the business school. He has previously worked as a doctor at St Thomas’ Hospital, part of Guy’s and St Thomas’ NHS Foundation Trust in London. Prior to that he was at a Swedish digital health start-up in product and commercial roles.

Karl on Linkedin

Manuela Widmer

Manuela joined Flerie in June 2025 as Assistant to the CEO Ted Fjällman. Originally from an insurance background as underwriter assistant and claim handler in Switzerland before following the call to move to the UK. Since then, she has worked in support roles in various sectors including working in the sales office of a salmon farm in Scotland.

She enjoys museums and galleries, a good cup of tea and splits her time between the UK and Switzerland.

Mark Quick

Mark joined Flerie in 2022 as a Partner having previously worked at Recipharm where he was Head of Corporate Development leading the M&A activities. He was also a member of the Executive Committee. Prior to that he held positions in ICI, Medeva, Celltech and UCB in various business development and supply chain roles. He is a board member of several of the Flerie portfolio companies both in drug development and commercial growth sectors. He has a first degree in Industrial Studies from Nottingham Trent University and an MBA from the Open Business School.

He enjoys the outdoors and in particular walking in the English Lake District is a lifelong fan of Formula One.

Mark on Linkedin

Michaela Gertz

Michaela is a senior advisor since August 2022. She has previously been CFO for the Nasdaq-listed biotech companies Immunicum and PledPharma, as well as held roles within fundraising and investor relations at Accelerator Nordic and ITP Invest. In addition to being a senior advisor at Flerie, she is a self-employed consultant working with CFO support, financing, IPOs and board assignments mostly in pharma/biotech. Michaela holds a MSc in Business and Economics from Uppsala University.

She enjoys travelling, playing golf and spending time in the archipelago.

Michaela on Linkedin

Paula Andersson

Paula joined Flerie in January 2024. Paula has co-founded a Swedish start-up and has a background in finance and private equity. She has previously held various roles in analysis and business development at Söderberg & Partners and Sobro. Paula holds a BSc in Business and Economics from Stockholm University, with additional law studies.

She enjoys skiing and spending time with family in the archipelago.

Ted Fjällman

Ted has been CEO of Flerie since January 2023, previously having been Partner, Venture Partner and the CEO of portfolio company Prokarium. He is board member of several drug development companies and was the first CEO of NorthX Biologics after Flerie acquired a manufacturing facility from Charles River to set up this CDMO.

Ted has previously worked in clinical research and strategy consulting and holds a PhD in Molecular Biology from the University of Guelph, Canada. He has served as committee member of the UK BioIndustry Association (BIA) and on the Management Board of the international Bacterial Vaccines Network (BactiVac). He also co-founded Tekiu, a knowledge transfer broker active internationally.

He enjoys travelling, cultural exchanges and languages and splits his time between Switzerland, Sweden and the UK.

Ted on Linkedin

Thomas Eldered

Thomas is executive chairman of Flerie since January 2023. He was the founder of Flerie in 2011 and was for more than a decade the sole shareholder and investor. Before that he co-founded the CDMO Recipharm in 1995, led the IPO in 2014 and finally left the company early 2021 when it was taken private again. Thomas is board member or chairman of the board in several portfolio companies. He holds a MSc in Industrial and Management Engineering from Linköping University.

Thomas enjoys hiking, cross country skiing and learning about other cultures.

Thomas on Linkedin